Crossmark

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Crossref DOI link: https://doi.org/10.15252/emmm.202013144

Published Online: 2021-03-04

Published Print: 2021-04-09

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Marrocco, Ilaria

Romaniello, Donatella

Vaknin, Itay

Drago‐Garcia, Diana https://orcid.org/0000-0001-6397-3123
Oren, Roni

Uribe, Mary Luz https://orcid.org/0000-0002-6567-2436
Belugali Nataraj, Nishanth https://orcid.org/0000-0003-2970-6739
Ghosh, Soma

Eilam, Raya

Salame, Tomer‐Meir

Lindzen, Moshit

Yarden, Yosef https://orcid.org/0000-0001-8578-0250
Funding

Funding for this research was provided by:

H2020 European Research Council (ERC740469)

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF15)
License Information

Version of Record valid from 2021-03-04
More Information

Publication History

Received: 2020-07-20

Accepted: 2021-02-02

Published: 2021-03-04